SHP2 Inhibitor

SHP2 Inhibitors (39):

Cat. No.	Product Name	Effect	Purity

HY-100388

SHP099	Inhibitor	99.80%
SHP099 is a potent, selective, orally available SHP2 inhibitor with an IC₅₀ of 70 nM.

HY-136173

Batoprotafib	Inhibitor	99.43%
Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC₅₀=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors.

HY-116009

RMC-4550	Inhibitor	99.32%
RMC-4550 is a potent, selective and allosteric inhibitor of SHP2, with an IC₅₀ of 0.583 nM.

HY-100388A

SHP099 hydrochloride	Inhibitor	99.92%
SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC₅₀ of 70 nM.

HY-141523

RMC-4630	Inhibitor	99.19%
RMC-4630 (SHP2-IN-7) is a SHP2 inhibitor extracted from patent WO2018013597.

HY-151464

SHP2/HDAC-IN-1	Inhibitor
SHP2/HDAC-IN-1 is a dual allosteric SHP2/HDAC inhibitor with IC₅₀ values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunotherapy.

HY-112478

PTP Inhibitor IV	Inhibitor
PTP Inhibitor IV is a protein tyrosine phosphatase (PTP) inhibitor that competitively inhibits DUSP14 phosphatase activity with an ₅₀ of 5.21 μM. PTP Inhibitor IV inhibits SHP-2, PTP1B, PTP-ε, PTP Meg-2, PTP-σ, PTP-β, and PTP-μ with ₅₀s of 1.8 μM, 2.5 μM, 8.4 μM, 13 μM, 20 μM, 6.4 μM, and 6.7 μM, respectively.

HY-152208

BPDA2	Inhibitor
BPDA2 is a highly selective and competitive active site SHP2 inhibitor with IC₅₀s of 92.0 nM, 33.39 μM, 40.71 μM for SHP2, SHP1, SHP1B, respectively. DBDA2 downregulates mitogenic and cell survival signaling and RTK expression. BPDA2 suppresses SHP2 mediated signaling and breast cancer cell phenotypes.

HY-18756

NSC-87877	Inhibitor	≥99.0%
NSC-87877 is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC₅₀ values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).

HY-100595

Sodium stibogluconate	Inhibitor	≥98.0%
Sodium stibogluconate (Stibogluconate trisodium nonahydrate) is a potent inhibitor of protein tyrosine phosphatase. Sodium stibogluconate inhibits 99% of SHP-1, SHP-2 and PTP1B activity at 10, 100, 100 μg/mL, respectively.

HY-134885

RMC-0331	Inhibitor	98.70%
RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction.

HY-137092

IACS-13909	Inhibitor	99.93%
IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC₅₀ of 15.7 nM and a K_d of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers.

HY-112368

PHPS1	Inhibitor	99.97%
PHPS1 is a potent and selective Shp2 inhibitor with K_is of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.

HY-131132A

SHP2-IN-6 hydrochloride	Inhibitor	98.74%
SHP2-IN-6 hydrochloride is a potent SHP2 inhibitor with an IC₅₀ of 25.8 nM. SHP2-IN-6 hydrochloride is extracted from patent WO2017211303A1, compound 7.

HY-114397

SHP394	Inhibitor	99.41%
SHP394 is an orally active, selective and allosteric inhibitor of SHP2, with an IC₅₀ of 23 nM.

HY-101964

SPI-112	Inhibitor
SPI-112 is a potent, selective and competitive SHP2 (PTPN11) inhibitor with IC₅₀s of 1 μM, 18.3 μM and 14.5 μM for SHP2, protein tyrosine phosphatase (PTP) and PTP1B, respectively.

HY-144903

Migoprotafib	Inhibitor	98.06%
Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor.

HY-121879

SHP836	Inhibitor	99.59%
SHP836 is a SHP2 allosteric inhibitor, with an IC₅₀ of 12 μM for the full length SHP2.

HY-108944

LYP-IN-1	Inhibitor	98.69%
LYP-IN-1 is a potent, selective and specific LYP inhibitor with a K_i and an IC₅₀ of 110 nM and 0.259 μM, respectively. LYP-IN-1 also has selectivity for a large panel of PTPs, such as SHP1 (IC₅₀=5 μM) and SHP2 (IC₅₀=2.5 μM). LYP-IN-1 exhibits highly efficacious cellular activity in T- and mast cells. LYP-IN-1 can be used for the study of autoimmune disorders.

HY-21336

3-Azetidinemethanol hydrochloride	Inhibitor	≥98.0%
3-Azetidinemethanol hydrochloride, a medical intermediate, can be used in the synthesis of SHP2 inhibitor.

Name
Email *

	Sorry, but the email address you supplied was invalid.